Related Experiment Video
Updated: May 13, 2026
Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer
Published on: May 20, 2016
Low-dose Computed Tomography Lung Cancer Screening Participants Show Improved 10-year Survival Compared With Matched
Robert Dziedzic1, Peter Kanyion1, Beata Koń2
1Department of Thoracic Surgery, Medical University of Gdansk, Gdansk, Poland.
Objectives:
This observational case-control study aims to evaluate the prevalence of comorbidities and 10-year overall survival in an LDCT-screened population compared to a propensity score-matched general Polish population.
Methods:
Aged 50-75 years (n=43,686) with at least 10 years of follow-up were included. The screening group (n=7281) underwent LDCT lung cancer screening between 2009 and 2011. The control group (n=36,405) was matched from the general population using 32 variables. The primary endpoint was 10-year overall survival; secondary endpoints included comorbidity prevalence and multivariate analysis results.
Results:
Common comorbidities included hypertension (52.2%), chronic coronary artery disease (20.5%), hypercholesterolemia (13.2%), and diabetes (13.0%). Multivariate analysis showed improved survival associated with LDCT screening (HR=0.653), hypertension (HR=0.882), hypercholesterolemia (HR=0.567), and female sex (HR=0.527). The 10-year overall survival was higher in the screening group by 5.6 percentage points (86.9%) compared with controls (81.3%, p<0.001).
Conclusions:
Participation in lung cancer screening using LDCT was associated with longer 10-year overall survival in adults aged 50-75 years. These results support the use of LDCT in high-risk individuals and emphasize the need for prospective studies to elucidate the mechanisms underlying the observed association.
